Boston Scientific Corporation (BSX)
Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-22 |
| Earnings Call | 2025-10-22 |
| Avg EPS Estimate | 0.7807 |
| Low EPS Estimate | 0.77 |
| High EPS Estimate | 0.8 |
| Revenue | |
| Avg Revenue Forecast | 5,277,797,090 |
| Low Revenue Forecast | 5,245,000,000 |
| High Revenue Forecast | 5,334,000,000 |
BSX Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $1,275,000,064 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.77 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.508 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $12,044,999,680 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
BSX Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $5,071,000,064 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $4,625,999,872 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $3,065,125,120 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 68.33% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 20.73% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 14.43% | Net profit margin, which reflects overall profitability. |
BSX Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 50.97% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $12,044,999,680 | Used together with cash and EBITDA to assess debt-paying ability. |
BSX Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 20.30% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 60.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for BSX (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $98.9 | Latest stock trading price |
| Price Target (High) | $140 | Analyst highest expected price |
| Price Target (Low) | $99 | Analyst lowest expected price |
| Price Target (Average) | $126.3 | Average target price across analysts |
| Price Target (Median) | $127 | Median of target prices |
| Average Rating Score | 1.32 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | strong_buy | Consensus rating |
| Analyst Coverage Count | 32 | Number of analysts providing estimates |
| Cash Holdings | $1,275,000,064 | Total cash held by the company |
| Cash per Share | $0.86 | Cash value per outstanding share |
| Total Debt | $12,044,999,680 | Company's total debt |
| Quick Ratio | 0.77 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.508 | Overall short-term liquidity |
| Debt/Equity Ratio | 50.97% | Leverage ratio: Debt / Equity |
| EBITDA | $5,071,000,064 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $19,349,000,192 | Total company revenue |
| Revenue per Share | $13.089 | Total revenue divided by shares outstanding |
| Gross Profit | 68.33% | Revenue minus cost of goods sold |
| Return on Assets | 5.76% | Net income / Total assets |
| Return on Equity | 12.49% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 60.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 20.30% | Year-over-year revenue growth |
| Gross Margin | 68.33% | Gross profit / Total revenue |
| EBITDA Margin | 26.21% | EBITDA / Revenue |
| Operating Margin | 20.73% | Operating income / Revenue |
| Profit Margin | 14.43% | Net income / Revenue |
| Free Cash Flow | $3,065,125,120 | Cash left after capital expenditures |
| Operating Cash Flow | $4,625,999,872 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |